文献速递特殊人群用药治疗药物监测与药物基因组学

维得利珠单抗妊娠期群体药代动力学模型与给药方案优化

Physiologically Motivated Sequential Population Modeling of Albumin Trends and Vedolizumab Pharmacokinetics for Pregnancy Dosing Regimen Optimization.
PubMed 文献 · Clin Pharmacol Ther · 2025-12-14

本研究基于39例妊娠IBD患者的维得利珠单抗浓度,采用序贯白蛋白趋势/群体PK建模,发现妊娠晚期 trough 浓度下降49.5%,中央分布容积增加52.4%、清除率增加38.6%,并模拟出缩短给药间隔的优化方案。

要点

  • 妊娠期白蛋白下降可作为血浆容量扩张的生物标志物用于PK建模。
  • 妊娠晚期维得利珠单抗谷浓度较孕前下降49.5%。
  • 约三分之一患者需缩短给药间隔以维持孕前有效暴露。

核心结论

  • 妊娠期维得利珠单抗暴露显著降低,需基于模型优化给药间隔以维持孕前有效暴露。

研究设计与样本

  • 纳入39例使用不同给药方案的妊娠IBD患者,采用序贯白蛋白趋势/群体PK建模,扩展已发表的维得利珠单抗非妊娠模型。

主要发现

  • 中央分布容积增加52.4%,清除率增加38.6%,妊娠晚期额外增加33.3个百分点,导致谷浓度下降49.5%。

关键数值与推荐

  • 为维持孕前有效暴露,约三分之一患者需逐渐缩短给药间隔,如孕前8周方案可缩短至最长5.6周。

临床怎么用

  • 可利用列线图样图优化妊娠期维得利珠单抗给药时间,以减轻不良妊娠结局风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The pharmacokinetics (PK) of monoclonal antibodies (mAbs) during pregnancy remains poorly characterized, despite active inflammatory bowel diseases (IBD) being the greatest risk factor for adverse pregnancy outcomes. To quantify pregnancy-induced changes, vedolizumab concentrations from 39 pregnant patients on various dosing regimens were analyzed using a sequential albumin-trend/PK modeling approach, extending a published vedolizumab non-pregnancy model. Albumin trends were first characterized using a polynomial mixed-effect model. Then, individual changes in albumin from their pre-pregnancy concentrations, implemented as time-varying patient-influential factor (covariate) in the PK model, served as potential biomarker of pregnancy-induced plasma volume expansion. The modeling framework allowed model-informed imputation of missing covariate data, extraction of hemodilution effect, and estimation of pre-pregnancy PK parameters. Due to albumin change, the central volume of distribution increased 52.4%, consistent with known gestational plasma volume expansion, while clearance increased to 38.6%. An additional third-trimester effect of gestational age, potentially reflecting transplacental transfer, increased clearance by an additional 33.3 percentage points. These changes led to a 49.5% decline in vedolizumab trough concentrations (Cmin) by late pregnancy. To maintain efficacious pre-pregnancy exposure (dependent on the individual dosing interval), dosing intervals were gradually shortened for approximately one-third (e.g., to up to 5.6 weeks for pre-pregnancy 8-week regimens). Optimized dosing times were summarized in an easy-to-use nomogram-like plot. This work provides the first population PK model of vedolizumab in pregnancy. By integrating physiologically motivated pregnancy effects, it advanced quantitative understanding of mAbs PK in pregnancy with potential application to other biologics and provides optimized dosing strategies to mitigate risks of adverse pregnancy outcomes.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Duvnjak Z, Michelet R, Steenholdt C, et al. Physiologically Motivated Sequential Population Modeling of Albumin Trends and Vedolizumab Pharmacokinetics for Pregnancy Dosing Regimen Optimization. Clin Pharmacol Ther. 2025. PMID: 41392610. doi:10.1002/cpt.70145

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。